{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T04:47:43Z","timestamp":1794890863849,"version":"4.9.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["NIH R01CA190306"],"award-info":[{"award-number":["NIH R01CA190306"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R00CA267171"],"award-info":[{"award-number":["R00CA267171"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["T32CA118681"],"award-info":[{"award-number":["T32CA118681"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA124435"],"award-info":[{"award-number":["P30CA124435"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["NIH R01CA273035"],"award-info":[{"award-number":["NIH R01CA273035"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["MBGII-24-1255495-01-MBG"],"award-info":[{"award-number":["MBGII-24-1255495-01-MBG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HA 9793\/1-1"],"award-info":[{"award-number":["HA 9793\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003887","name":"International Myeloma Foundation","doi-asserted-by":"publisher","award":["Career Development Award"],"award-info":[{"award-number":["Career Development Award"]}],"id":[{"id":"10.13039\/100003887","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The development of effective antibody therapeutics has been hampered by a lack of methods to measure drug delivery and activity within tumors at single-cell resolution. Here we introduce single-cell spatial pharmacobiology (SSP), an experimental and analytical framework that integrates in situ imaging of a systemically infused, fluorescently labeled therapeutic antibody with high-plex spatial proteomics to quantify antibody distribution, target engagement and tumor microenvironment (TME) architecture. We applied SSP to tumor tissues from participants with head and neck squamous cell carcinoma and pancreatic ductal adenocarcinoma who received the antibody panitumumab-IRDye800 in phase 1 trials. SSP identified pronounced spatial heterogeneity in single-cell drug delivery and target engagement, shaped by conserved stromal barriers, including periostin-rich extracellular matrix assemblies and fibroblast-activation-protein-positive cancer-associated fibroblast neighborhoods, which were associated with reduced antibody delivery in both tumor types. SSP measures drug\u2013target\u2013TME interactions in human tumors and can support studies of resistance mechanisms, dosing strategies and discovery of spatial biomarkers for precision oncology.<\/jats:p>","DOI":"10.1038\/s41587-026-03152-x","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:03:30Z","timestamp":1780477410000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Single-cell spatial pharmacobiology identifies conserved stromal barriers to therapeutic antibody delivery in human solid tumors"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5023-3465","authenticated-orcid":false,"given":"Guolan","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6720-7570","authenticated-orcid":false,"given":"Maximilian","family":"Haist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xulei","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Naveed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erna","family":"Forgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-A.","family":"Baertsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Mani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Rovira-Clav\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Finegersh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4079-7969","authenticated-orcid":false,"given":"Yury","family":"Goltsev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3580-1348","authenticated-orcid":false,"given":"Chiara","family":"Caraccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nynke S.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Hom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deana R.","family":"Colburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brock A.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2098-6842","authenticated-orcid":false,"given":"Christina S.","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6602-6372","authenticated-orcid":false,"given":"Natalie S.","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Dimitrios","family":"Colevas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7570-2080","authenticated-orcid":false,"given":"Greg M.","family":"Thurber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Poultsides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8862-9043","authenticated-orcid":false,"given":"Garry P.","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0294-5203","authenticated-orcid":false,"given":"Eben L.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"3152_CR1","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1016\/j.cell.2022.05.029","volume":"185","author":"PJ Carter","year":"2022","unstructured":"Carter, P. J. & Rajpal, A. Designing antibodies as therapeutics. Cell 185, 2789\u20132805 (2022).","journal-title":"Cell"},{"key":"3152_CR2","doi-asserted-by":"publisher","first-page":"2153410","DOI":"10.1080\/19420862.2022.2153410","volume":"15","author":"H Kaplon","year":"2023","unstructured":"Kaplon, H., Crescioli, S., Chenoweth, A., Visweswaraiah, J. & Reichert, J. M. Antibodies to watch in 2023. MAbs 15, 2153410 (2023).","journal-title":"MAbs"},{"key":"3152_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s43018-023-00516-z","volume":"4","author":"S Zinn","year":"2023","unstructured":"Zinn, S. et al. Advances in antibody-based therapy in oncology. Nat. Cancer 4, 165\u2013180 (2023).","journal-title":"Nat. Cancer"},{"key":"3152_CR4","first-page":"447","volume":"15","author":"A Mullard","year":"2016","unstructured":"Mullard, A. Parsing clinical success rates. Nat. Rev. Drug Discov. 15, 447\u2013447 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3152_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"CH Wong","year":"2019","unstructured":"Wong, C. H., Siah, K. W. & Lo, A. W. Estimation of clinical trial success rates and related parameters. Biostatistics 20, 273\u2013286 (2019).","journal-title":"Biostatistics"},{"key":"3152_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","volume":"24","author":"S Paul","year":"2024","unstructured":"Paul, S. et al. Cancer therapy with antibodies. Nat. Rev. Cancer 24, 399\u2013426 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"3152_CR7","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455\u20132465 (2012).","journal-title":"N. Engl. J. Med."},{"key":"3152_CR8","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/bcp.14543","volume":"87","author":"R Longuesp\u00e9e","year":"2021","unstructured":"Longuesp\u00e9e, R. et al. Approaching sites of action of drugs in clinical pharmacology: new analytical options and their challenges. Br. J. Clin. Pharmacol. 87, 858\u2013874 (2021).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"3152_CR9","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","volume":"24","author":"F Bensch","year":"2018","unstructured":"Bensch, F. et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat. Med. 24, 1852\u20131858 (2018).","journal-title":"Nat. Med."},{"key":"3152_CR10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/cpt.1211","volume":"106","author":"IH Bartelink","year":"2019","unstructured":"Bartelink, I. H. et al. Tumor drug penetration measurements could be the neglected piece of the personalized cancer treatment puzzle. Clin. Pharmacol. Ther. 106, 148\u2013163 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"key":"3152_CR11","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.1200\/JCO.2015.62.8719","volume":"33","author":"DV Catenacci","year":"2015","unstructured":"Catenacci, D. V. et al. Randomized phase Ib\/II study of gemcitabine plus placebo or vismodegib, a Hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer. J. Clin. Oncol. 33, 4284\u20134292 (2015).","journal-title":"J. Clin. Oncol."},{"key":"3152_CR12","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.21037\/jgo-22-86","volume":"13","author":"KL Aung","year":"2022","unstructured":"Aung, K. L. et al. A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma. J. Gastrointest. Oncol. 13, 3216\u20133226 (2022).","journal-title":"J. Gastrointest. Oncol."},{"key":"3152_CR13","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1200\/JCO.2003.02.098","volume":"21","author":"MJ Moore","year":"2003","unstructured":"Moore, M. J. et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 21, 3296\u20133302 (2003).","journal-title":"J. Clin. Oncol."},{"key":"3152_CR14","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1200\/JCO.2020.38.4_suppl.638","volume":"38","author":"MA Tempero","year":"2020","unstructured":"Tempero, M. A. et al. HALO 109-301: a randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20)\u2009+\u2009nab-paclitaxel\/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA). J. Clin. Oncol. 38, 638 (2020).","journal-title":"J. Clin. Oncol."},{"key":"3152_CR15","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41416-019-0683-3","volume":"122","author":"A De Jesus-Acosta","year":"2020","unstructured":"De Jesus-Acosta, A. et al. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. Br. J. Cancer 122, 498\u2013505 (2020).","journal-title":"Br. J. Cancer"},{"key":"3152_CR16","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia, J. et al. Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat. Rev. 86, 102017 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"3152_CR17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert, M. R. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 699\u2013708 (2014).","journal-title":"N. Engl. J. Med."},{"key":"3152_CR18","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.7150\/thno.24487","volume":"8","author":"RW Gao","year":"2018","unstructured":"Gao, R. W. et al. Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers. Theranostics 8, 2488\u20132495 (2018).","journal-title":"Theranostics"},{"key":"3152_CR19","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S2468-1253(20)30088-1","volume":"5","author":"G Lu","year":"2020","unstructured":"Lu, G. et al. Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalation study. Lancet Gastroenterol. Hepatol. 5, 753\u2013764 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"3152_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11307-020-01536-2","volume":"23","author":"J Pei","year":"2021","unstructured":"Pei, J. et al. Safety and stability of antibody\u2013dye conjugate in optical molecular imaging. Mol Imaging Biol. 23, 109\u2013116 (2021).","journal-title":"Mol Imaging Biol."},{"key":"3152_CR21","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41587-021-01094-0","volume":"40","author":"NF Greenwald","year":"2022","unstructured":"Greenwald, N. F. et al. Whole-cell segmentation of tissue images with human-level performance using large-scale data annotation and deep learning. Nat. Biotechnol. 40, 555\u2013565 (2022).","journal-title":"Nat. Biotechnol."},{"key":"3152_CR22","doi-asserted-by":"publisher","first-page":"981825","DOI":"10.3389\/fimmu.2022.981825","volume":"13","author":"G Lu","year":"2022","unstructured":"Lu, G. et al. A real-time GPU-accelerated parallelized image processor for large-scale multiplexed fluorescence microscopy data. Front. Immunol. 13, 981825 (2022).","journal-title":"Front. Immunol."},{"key":"3152_CR23","doi-asserted-by":"publisher","first-page":"8999","DOI":"10.1073\/pnas.92.19.8999","volume":"92","author":"T Saga","year":"1995","unstructured":"Saga, T. et al. Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc. Natl Acad. Sci. USA 92, 8999\u20139003 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3152_CR24","first-page":"814s","volume":"50","author":"RK Jain","year":"1990","unstructured":"Jain, R. K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 50, 814s\u2013819s (1990).","journal-title":"Cancer Res."},{"key":"3152_CR25","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","volume":"60","author":"GM Thurber","year":"2008","unstructured":"Thurber, G. M., Schmidt, M. M. & Wittrup, K. D. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv. Drug Deliv. Rev. 60, 1421\u20131434 (2008).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"3152_CR26","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.cell.2018.07.010","volume":"174","author":"Y Goltsev","year":"2018","unstructured":"Goltsev, Y. et al. Deep profiling of mouse splenic architecture with CODEX multiplexed imaging. Cell 174, 968\u2013981 (2018).","journal-title":"Cell"},{"key":"3152_CR27","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.cell.2020.07.005","volume":"182","author":"CM Sch\u00fcrch","year":"2020","unstructured":"Sch\u00fcrch, C. M. et al. Coordinated cellular neighborhoods orchestrate antitumoral immunity at the colorectal cancer invasive front. Cell 182, 1341\u20131359 (2020).","journal-title":"Cell"},{"key":"3152_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26974-6","volume":"12","author":"D Phillips","year":"2021","unstructured":"Phillips, D. et al. Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma. Nat. Commun. 12, 6726 (2021).","journal-title":"Nat. Commun."},{"key":"3152_CR29","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-023-05915-x","volume":"619","author":"JW Hickey","year":"2023","unstructured":"Hickey, J. W. et al. Organization of the human intestine at single-cell resolution. Nature 619, 572\u2013584 (2023).","journal-title":"Nature"},{"key":"3152_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00281-022-00974-0","volume":"45","author":"W Kuswanto","year":"2023","unstructured":"Kuswanto, W., Nolan, G. & Lu, G. Highly multiplexed spatial profiling with CODEX: bioinformatic analysis and application in human disease. Semin. Immunopathol. 45, 145\u2013157 (2023).","journal-title":"Semin. Immunopathol."},{"key":"3152_CR31","first-page":"2497","volume":"60","author":"PA Netti","year":"2000","unstructured":"Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J. & Jain, R. K. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 60, 2497\u20132503 (2000).","journal-title":"Cancer Res."},{"key":"3152_CR32","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/sj.bjc.6600270","volume":"86","author":"CdeL Davies","year":"2002","unstructured":"Davies, CdeL., Berk, D. A., Pluen, A. & Jain, R. K. Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells. Br. J. Cancer 86, 1639\u20131644 (2002).","journal-title":"Br. J. Cancer"},{"key":"3152_CR33","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1158\/1078-0432.CCR-18-2684","volume":"25","author":"H Wang","year":"2019","unstructured":"Wang, H. et al. Elastography can map the local inverse relationship between shear modulus and drug delivery within the pancreatic ductal adenocarcinoma microenvironment. Clin. Cancer Res. 25, 2136\u20132143 (2019).","journal-title":"Clin. Cancer Res."},{"key":"3152_CR34","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.cell.2009.10.027","volume":"139","author":"KR Levental","year":"2009","unstructured":"Levental, K. R. et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139, 891\u2013906 (2009).","journal-title":"Cell"},{"key":"3152_CR35","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai, E. et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat. Rev. Cancer 20, 174\u2013186 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"3152_CR36","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.cell.2023.03.016","volume":"186","author":"Y Chhabra","year":"2023","unstructured":"Chhabra, Y. & Weeraratna, A. T. Fibroblasts in cancer: unity in heterogeneity. Cell 186, 1580\u20131609 (2023).","journal-title":"Cell"},{"key":"3152_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.cels.2021.09.012","volume":"13","author":"SS Bhate","year":"2022","unstructured":"Bhate, S. S., Barlow, G. L., Sch\u00fcrch, C. M. & Nolan, G. P. Tissue schematics map the specialization of immune tissue motifs and their appropriation by tumors. Cell Syst. 13, 109\u2013130 (2022).","journal-title":"Cell Syst."},{"key":"3152_CR38","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.cell.2017.10.044","volume":"171","author":"SV Puram","year":"2017","unstructured":"Puram, S. V. et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell. 171, 1611\u20131624 (2017).","journal-title":"Cell."},{"key":"3152_CR39","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0192-0561(92)90176-L","volume":"14","author":"JN Weinstein","year":"1992","unstructured":"Weinstein, J. N. & van Osdol, W. The macroscopic and microscopic pharmacology of monoclonal antibodies. Int. J. Immunopharmacol 14, 457\u2013463 (1992).","journal-title":"Int. J. Immunopharmacol"},{"key":"3152_CR40","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1158\/1535-7163.MCT-17-0019","volume":"16","author":"F Li","year":"2017","unstructured":"Li, F. et al. Tumor-associated macrophages can contribute to antitumor activity through Fc\u03b3R-mediated processing of antibody\u2013drug conjugates. Mol Cancer Ther. 16, 1347\u20131354 (2017).","journal-title":"Mol Cancer Ther."},{"key":"3152_CR41","doi-asserted-by":"publisher","first-page":"eaal3604","DOI":"10.1126\/scitranslmed.aal3604","volume":"9","author":"SP Arlauckas","year":"2017","unstructured":"Arlauckas, S. P. et al. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci. Transl. Med. 9, eaal3604 (2017).","journal-title":"Sci. Transl. Med."},{"key":"3152_CR42","doi-asserted-by":"publisher","first-page":"1144056","DOI":"10.3389\/fonc.2023.1144056","volume":"13","author":"R Murphy","year":"2023","unstructured":"Murphy, R., Halford, S. & Symeonides, S. N. Project Optimus, an FDA initiative: considerations for cancer drug development internationally, from an academic perspective. Front. Oncol. 13, 1144056 (2023).","journal-title":"Front. Oncol."},{"key":"3152_CR43","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1200\/JCO.22.00371","volume":"40","author":"J Fourie Zirkelbach","year":"2022","unstructured":"Fourie Zirkelbach, J. et al. Improving dose-optimization processes used in oncology drug development to minimize toxicity and maximize benefit to patients. J. Clin. Oncol. 40, 3489\u20133500 (2022).","journal-title":"J. Clin. Oncol."},{"key":"3152_CR44","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41568-020-00329-7","volume":"21","author":"TR Cox","year":"2021","unstructured":"Cox, T. R. The matrix in cancer. Nat. Rev. Cancer 21, 217\u2013238 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"3152_CR45","doi-asserted-by":"publisher","first-page":"eaaz0868","DOI":"10.1126\/science.aaz0868","volume":"370","author":"HT Nia","year":"2020","unstructured":"Nia, H. T., Munn, L. L. & Jain, R. K. Physical traits of cancer. Science 370, eaaz0868 (2020).","journal-title":"Science"},{"key":"3152_CR46","doi-asserted-by":"publisher","first-page":"M111.014647","DOI":"10.1074\/mcp.M111.014647","volume":"11","author":"A Naba","year":"2012","unstructured":"Naba, A. et al. The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol. Cell. Proteomics 11, M111.014647 (2012).","journal-title":"Mol. Cell. Proteomics"},{"key":"3152_CR47","doi-asserted-by":"publisher","first-page":"19609","DOI":"10.1073\/pnas.1908626116","volume":"116","author":"C Tian","year":"2019","unstructured":"Tian, C. et al. Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells. Proc. Natl Acad. Sci. USA 116, 19609\u201319618 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3152_CR48","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.matbio.2015.06.003","volume":"49","author":"A Naba","year":"2016","unstructured":"Naba, A. et al. The extracellular matrix: tools and insights for the \u2018omics\u2019 era. Matrix Biol. 49, 10\u201324 (2016).","journal-title":"Matrix Biol."},{"key":"3152_CR49","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1016\/j.bpj.2010.08.065","volume":"99","author":"T Stylianopoulos","year":"2010","unstructured":"Stylianopoulos, T., Diop-Frimpong, B., Munn, L. L. & Jain, R. K. Diffusion anisotropy in collagen gels and tumors: the effect of fiber network orientation. Biophys. J. 99, 3119\u20133128 (2010).","journal-title":"Biophys. J."},{"key":"3152_CR50","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1158\/2159-8290.CD-20-1484","volume":"12","author":"KM McAndrews","year":"2022","unstructured":"McAndrews, K. M. et al. Identification of functional heterogeneity of carcinoma-associated fibroblasts with distinct IL6-mediated therapy resistance in pancreatic cancer. Cancer Discov. 12, 1580\u20131597 (2022).","journal-title":"Cancer Discov."},{"key":"3152_CR51","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-19-2238","volume":"26","author":"M Fabre","year":"2020","unstructured":"Fabre, M. et al. OMTX705, a novel FAP-targeting ADC demonstrates activity in chemotherapy and pembrolizumab-resistant solid tumor models. Clin. Cancer Res. 26, 3420\u20133430 (2020).","journal-title":"Clin. Cancer Res."},{"key":"3152_CR52","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/ITT.S291767","volume":"10","author":"R Bughda","year":"2021","unstructured":"Bughda, R., Dimou, P., D\u2019Souza, R. R. & Klampatsa, A. Fibroblast activation protein (FAP)-targeted CAR-T cells: launching an attack on tumor stroma. Immunotargets Ther. 10, 313\u2013323 (2021).","journal-title":"Immunotargets Ther."},{"key":"3152_CR53","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2967\/jnumed.119.241232","volume":"61","author":"J Calais","year":"2020","unstructured":"Calais, J. FAP: the next billion dollar nuclear theranostics target? J. Nucl. Med. 61, 163\u2013165 (2020).","journal-title":"J. Nucl. Med."},{"key":"3152_CR54","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1158\/1078-0432.CCR-19-3717","volume":"26","author":"G Lu","year":"2020","unstructured":"Lu, G. et al. Predicting therapeutic antibody delivery into human head and neck cancers. Clin. Cancer Res. 26, 2582\u20132594 (2020).","journal-title":"Clin. Cancer Res."},{"key":"3152_CR55","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1002\/eji.202048891","volume":"51","author":"J Kennedy-Darling","year":"2021","unstructured":"Kennedy-Darling, J. et al. Highly multiplexed tissue imaging using repeated oligonucleotide exchange reaction. Eur. J. Immunol. 51, 1262\u20131277 (2021).","journal-title":"Eur. J. Immunol."},{"key":"3152_CR56","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1038\/s41596-021-00556-8","volume":"16","author":"S Black","year":"2021","unstructured":"Black, S. et al. CODEX multiplexed tissue imaging with DNA-conjugated antibodies. Nat. Protoc. 16, 3802\u20133835 (2021).","journal-title":"Nat. Protoc."},{"key":"3152_CR57","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.ccell.2026.01.003","volume":"44","author":"M Haist","year":"2026","unstructured":"Haist, M. et al. Lymph node colonization induces tissue remodeling via immunosuppressive fibroblast-myeloid cell niches supporting metastatic tolerance. Cancer Cell 44, 604\u2013623 (2026).","journal-title":"Cancer Cell"},{"key":"3152_CR58","doi-asserted-by":"publisher","unstructured":"Haist, M. et al. Lymph node colonization induces tissue remodeling via immunosuppressive fibroblast-myeloid cell niches supporting metastatic tolerance. Cancer Cell https:\/\/doi.org\/10.1016\/j.ccell.2026.01.003 (2026).","DOI":"10.1016\/j.ccell.2026.01.003"},{"key":"3152_CR59","doi-asserted-by":"publisher","first-page":"1070203","DOI":"10.3389\/fimmu.2023.1070203","volume":"14","author":"M Haist","year":"2023","unstructured":"Haist, M. et al. Response to primary chemoradiotherapy of locally advanced oropharyngeal carcinoma is determined by the degree of cytotoxic T cell infiltration within tumor cell aggregates. Front. Immunol. 14, 1070203 (2023).","journal-title":"Front. Immunol."},{"key":"3152_CR60","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1109\/83.506761","volume":"5","author":"BS Reddy","year":"1996","unstructured":"Reddy, B. S. & Chatterji, B. N. An FFT-based technique for translation, rotation, and scale-invariant image registration. IEEE Trans. Image Process. 5, 1266\u20131271 (1996).","journal-title":"IEEE Trans. Image Process."},{"key":"3152_CR61","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1016\/j.neuroimage.2008.10.040","volume":"45","author":"T Vercauteren","year":"2009","unstructured":"Vercauteren, T., Pennec, X., Perchant, A. & Ayache, N. Diffeomorphic demons: efficient non-parametric image registration. Neuroimage 45, S61\u2013S72 (2009).","journal-title":"Neuroimage"},{"key":"3152_CR62","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S1361-8415(98)80022-4","volume":"2","author":"JP Thirion","year":"1998","unstructured":"Thirion, J. P. Image matching as a diffusion process: an analogy with Maxwell\u2019s demons. Med. Image Anal. 2, 243\u2013260 (1998).","journal-title":"Med. Image Anal."},{"key":"3152_CR63","doi-asserted-by":"publisher","first-page":"727626","DOI":"10.3389\/fimmu.2021.727626","volume":"12","author":"JW Hickey","year":"2021","unstructured":"Hickey, J. W., Tan, Y., Nolan, G. P. & Goltsev, Y. Strategies for accurate cell type identification in CODEX multiplexed imaging data. Front. Immunol. 12, 727626 (2021).","journal-title":"Front. Immunol."},{"key":"3152_CR64","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1046\/j.1466-822X.2003.00015.x","volume":"12","author":"IF Spellerberg","year":"2003","unstructured":"Spellerberg, I. F. & Fedor, P. J. A tribute to Claude Shannon (1916\u20132001) and a plea for more rigorous use of species richness, species diversity and the \u2018Shannon\u2013Wiener\u2019Index. Global Ecol. Biogeogr. 12, 177\u2013179 (2003).","journal-title":"Global Ecol. Biogeogr."},{"key":"3152_CR65","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1109\/TIP.2006.875205","volume":"15","author":"U Adiga","year":"2006","unstructured":"Adiga, U., Malladi, R., Fernandez-Gonzalez, R. & Ortiz de Solorzano, C. High-throughput analysis of multispectral images of breast cancer tissue. IEEE Trans. Image Process. 15, 2259\u20132268 (2006).","journal-title":"IEEE Trans. Image Process."},{"key":"3152_CR66","doi-asserted-by":"publisher","first-page":"113494","DOI":"10.1016\/j.celrep.2023.113494","volume":"42","author":"JW Hickey","year":"2023","unstructured":"Hickey, J. W. et al. T cell-mediated curation and restructuring of tumor tissue coordinates an effective immune response. Cell Rep. 42, 113494 (2023).","journal-title":"Cell Rep."},{"key":"3152_CR67","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41587-020-0472-9","volume":"38","author":"CR Merritt","year":"2020","unstructured":"Merritt, C. R. et al. Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat. Biotechnol. 38, 586\u2013599 (2020).","journal-title":"Nat. Biotechnol."},{"key":"3152_CR68","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/978-1-0716-0623-0_21","volume":"2148","author":"DR Zollinger","year":"2020","unstructured":"Zollinger, D. R., Lingle, S. E., Sorg, K., Beechem, J. M. & Merritt, C. R. GeoMx\u2122 RNA assay: high multiplex, digital, spatial analysis of RNA in FFPE tissue. Methods Mol. Biol. 2148, 331\u2013345 (2020).","journal-title":"Methods Mol. Biol."},{"key":"3152_CR69","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1093\/nar\/gkad1026","volume":"52","author":"N Liu","year":"2024","unstructured":"Liu, N. et al. standR: spatial transcriptomic analysis for GeoMx DSP data. Nucleic Acids Res. 52, e2 (2024).","journal-title":"Nucleic Acids Res."},{"key":"3152_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2014-15-2-r29","volume":"15","author":"CW Law","year":"2014","unstructured":"Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).","journal-title":"Genome Biol."},{"key":"3152_CR71","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"}],"container-title":["Nature Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41587-026-03152-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-026-03152-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-026-03152-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:03:51Z","timestamp":1780920231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41587-026-03152-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":71,"alternative-id":["3152"],"URL":"https:\/\/doi.org\/10.1038\/s41587-026-03152-x","relation":{},"ISSN":["1087-0156","1546-1696"],"issn-type":[{"value":"1087-0156","type":"print"},{"value":"1546-1696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.P.N. and Y.G. have equity in Akoya Biosciences and G.P.N is a scientific advisory board member of Akoya Biosciences. Akoya Biosciences makes reagents and instruments that are dependent on licenses from Stanford University. Stanford University has been granted US patent 9909167, which covers some aspects of the technology described in this paper. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}